Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis-Reference-Cited by-同舟云学术

Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis

Published:2022-04-08 Issue:8 Volume:88 Page:3837-3846
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Mauer Jonathan¹^ORCID,Bullok Kristin²^ORCID,Watt Stephen¹^ORCID,Whalen Ed¹^ORCID,Russo Leo¹^ORCID,Junor Rod¹^ORCID,Markman John³^ORCID,Hauber Brett¹⁴^ORCID,Tervonen Tommi⁵^ORCID

Affiliation:

1. Pfizer New York NY USA

2. Eli Lilly & Co., Global Patient Safety Indianapolis IN USA

3. Translational Pain Research Program, Department of Neurosurgery University of Rochester Rochester NY USA

4. CHOICE Institute University of Washington School of Pharmacy Seattle WA USA

5. Evidera London UK

Funder

Eli Lilly and Company

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15309

Reference51 articles.

1. Osteoarthritis year in review 2019: epidemiology and therapy

2. Adverse Effects of Analgesics Commonly Used by Older Adults With Osteoarthritis: Focus on Non-Opioid and Opioid Analgesics

3. Opioid Therapy for Osteoarthritis and Chronic Low Back Pain

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the balance of benefits and harms in chronic pain clinical trials: prioritizing individual participants over individual outcomes;Regional Anesthesia & Pain Medicine;2023-11-14

2. Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma;Value in Health;2023-06

3. Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force;Value in Health;2023-04